Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder

Abstract

IMPORTANCE Despite the widespread awareness of functional magnetic resonance imaging findings suggesting a role for cortical connectivity networks in treatment selection for major depressive disorder, its clinical utility remains limited. Recent methodological advances have revealed functional magnetic resonance imaging-like connectivity networks using electroencephalography (EEG), a tool more easily implemented in clinical practice. OBJECTIVE To determine whether EEG connectivity could reveal neural moderators of antidepressant treatment. DESIGN, SETTING, AND PARTICIPANTS In this nonprespecified secondary analysis, data were analyzed from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinic Care study, a placebo-controlled, double-blinded randomized clinical trial. Recruitment began July 29, 2011, and was completed December 15, 2015. A random sample of 221 outpatients with depression aged 18 to 65 years who were not taking medication for depression was recruited and assessed at 4 clinical sites. Analysis was performed on an intent-to-treat basis. Statistical analysis was performed from November 16, 2018, to May 23, 2019. INTERVENTIONS Patients received either the selective serotonin reuptake inhibitor sertraline hydrochloride or placebo for 8 weeks.MAIN OUTCOMES AND MEASURES Electroencephalographic orthogonalized power envelope connectivity analyses were applied to resting-state EEG data. Intent-to-treat prediction linear mixed models were used to determine which pretreatment connectivity patterns were associated with response to sertraline vs placebo. The primary clinical outcome was the total score on the 17-item Hamilton Rating Scale for Depression, administered at each study visit. RESULTSOf the participants recruited, 9 withdrew after first dose owing to reported adverse effects, and 221 participants (150 women; mean [SD] age, 37.8 [12.7] years) underwent EEG recordings and had high-quality pretreatment EEG data. After correction for multiple comparisons, connectome-wide analyses revealed moderation by connections within and between widespread cortical regions-most prominently parietal-for both the antidepressant and placebo groups. Greater alpha-band and lower gamma-band connectivity predicted better placebo outcomes and worse antidepressant outcomes. Lower connectivity levels in these moderating connections were associated with higher levels of anhedonia. Connectivity features that moderate treatment response differentially by treatment group were distinct from connectivity features that change from baseline to 1 week into treatment. The group mean (SD) score on the 17-item Hamilton Rating Scale for Depression was 18.35 (4.58) at baseline and 26.14 (30.37) across all time points. CONCLUSIONS AND RELEVANCE These findings establish the utility of EEG-based network functional connectivity analyses for differentiating between responses to an antidepressant vs placebo. A role emerged for parietal cortical regions in predicting placebo outcome. From a treatment perspective, capital...

One size does not fit all: Single-subject analyses reveal substantial individual variation in electroencephalography (EEG) characteristics of antidepressant treatment response

“…Depending on the EEG characteristic and how it was MSE identified, 39-61% of our sample did not unambiguously show the same outcomes as their group, which is consistent with the idea that multiple response patterns to antidepressant treatment exist [50]. Taking alpha connectivity as an example, recent work shows that alpha connectivity profiles may differentially predict response to placebo versus antidepressant pharmacotherapy (setraline; [51]), highlighting the possibility that different alpha connectivity patterns may distinguish responders to different types of interventions. The decrease in alpha connectivity in treatment responders using group analyses in this and previous studies might thus only represent one of several response profiles that exist in patients with MDD.…”

Modulation of functional network properties in major depressive disorder following electroconvulsive therapy (ECT): a resting-state EEG analysis

“…For example, a large EEG study by Iseger et al 62 showed reduced alpha connectivity in male responders to a trial of antidepressant medication (Escitalopram, Sertraline, or Venlafaxine-XR). Pre-treatment alpha, beta, and gamma band connectivity has also been shown to moderate antidepressant (sertraline hydrochloride or placebo) treatment outcome in a recent large multi-centre study using a novel power envelope connectivity approach 63 ; while lower pre-treatment alpha-band connectivity has been observed in responders to ECT 64 . Although further work is needed to better elucidate the underlying mechanisms responsible for the observed connectivity changes in the present study, a recently proposed connectivity resetting hypothesis 9 might aid in partially explaining these findings.…”

Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG

“…Furthermore, several potential resting state markers exist for predicting treatment outcome in major depression, such as frontal alpha asymmetry, 38 prefrontal theta cordance, 39 pretreatment rostral anterior cingulate theta activity, 40 antidepressant treatment response (ATR) index, 41 and EEG functional connectivity. 42 Other resting-state EEGbased biomarkers are promising for the identification of patients at risk of mild cognitive impairment due to Alzheimer's and Lewy body disease, 43 and for subtyping subjects with attention deficit hyperactivity disorder (ADHD). 44 EEG is also used to monitor the effects of certain drugs, like lithium carbonate used in the treatment of bipolar disorder.…”